WELCOME TO

The BREW Project

Medium and long-term opportunities and risks of the biotechnological production of bulk

chemicals from renewable resources   

Fraunhofer

ISI

InstituteSystems andInnovation Research

CERISS

BREW - Organisational issues

1. Consortium

2. Finances & roles of partners

3. Contract changes

4. Product overview

5. Book proposal

6. BREW website (members‘ section)

7. Cost statements

8. Time plan

1. Consortium

• Dechema taking over conference (WP9)

• ACTIN out, UU taking over Projection of the market potential (WP 6)

2. Finances & roles of partners

• No financial contribution to Dechema for organizing conference (but EUR 5000 for inviting experts from abroad)

• Saved funds for calculating investment costs of biorecovery by DSM

3. Contract changes (revised DoW not yet submitted to EU)

• Extra funds for DSM for investment costs

• Degussa and novozymes IN

• Actin OUT

• UU takes over WP 6 from Actin, more consumables

• More travel funds for UCM

• DuPont as “Full cost” partner

• ATO A&FI

• Contract extension to May 2005

4. Product overview / BREWtool (1/2)ATO     (Biotech) Hydrogen

    PHA    Lysine: OUT    Adipic acid: Generic approach

BP     Acetic acid (via ATO)    Support on petchem. data

Cargill DOW     LA    PLA    Corn growing    CWM    IFEU (anaerobic digestion?), NREL?,

DSM     various petchem. and biotech products

DuPont     PDO

Shell     Ethylene (via bioethanol)    LA    Ethyl lactate     Methyl ethyl ketone    Adipic acid

4. Product overview / BREWtool (2/2)UCM

   Diglycerol monooleate (biosurfactant)    Diglycerol monolaureate (biosurfactant)

   Glycerol monopalmitate (biosurfactant)    Glycerol monoricinolate (biosurfactant)

   Glycerol monooleate (biosurfactant)

   Oleyl oleate (biolubricant)

   Isopropyl myristate (Cosmetics)

   n-Octyl octanoate (Cosmetics) – Ester

   Maybe: Biodiesel from used frying oils and methanol

    Products obtained by nucleophilic enzymatic opening of epoxides (intermediates of pharmaceutical products e.g. polyfunctionalized molecules)

Uniqema Multiple products from enzymatic processing pathways.

    Splitting of fats and oils to

a)  fatty acid

b)  glycerin (co-product: RME)

    Transesterification of rapeseed oil with methanol natural alcohol ex methylester surfactant production

Novozymes

    see above

Roquette     LCA starch to glucose/dextrose

Degussa     PDO (pchem)

    Acrylamide (biotech)

5. Book proposal

• Reviews received

• Decision tomorrow

http://www.chem.uu.nl/brew

username: brewer

password: bulk

• Second edition of the Description of Work

• Section “BREW Book Publication”: First book proposal

• Crank, M. et al.: Techno-economic Feasibility of Large-scale Production of Bio-based Polymers in Europe (PRO-BIP)

• Andringa, L.: Analysis of technology policy and systems of innovation approach: the case of biopolymers in the United States, M.Sc. Thesis Utrecht University/University of Oklahoma

• Recent publications by others (e.g., JoIE)

• Upcoming conferences

6. BREW website, members‘ section

7. Cost statements

• Cost statements only received from: Fraunhofer, novozymes AND A&FI

• Please ask you administration to send A.S.A.P. !

8. Time plan (1/2)

• Substructure interim report circulated by 18 JUNE

• Final decision about substructure interim report by 30 JUNE

• Fourth plenary meeting: SEPT/OCT 2004

• Fifth plenary meeting: DEC/JAN 2005?

• Conference: 10-12 MAY 2005

8. Time plan (2/2)1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Ap

r-0

3

Ma

y-0

3

Jun

-03

Jul-

03

Au

g-0

3

Se

p-0

3

Oct

-03

No

v-0

3

De

c-0

3

Jan

-04

Fe

b-0

4

Ma

r-0

4

Ap

r-0

4

Ma

y-0

4

Jun

-04

Jul-

04

Au

g-0

4

Se

p-0

4

Oct

-04

No

v-0

4

De

c-0

4

Jan

-05

Fe

b-0

5

Ma

r-0

5

Ap

r-0

5

Ma

y-0

5

1.Overview of biotech- nological processes

Fh-ISI, PRI, UCM, A&FI, all companies

11.6

2.Technical and economic characteristics

UU, Fh-ISI, UCM, A&FI, all companies

23.6

3.Environmental and economic assessment

UU, DSM 5.7

4.Taxonomy of risks and risk assessment

PRI, UCM, A&FI 9.95

5. Public perception CERISS, Fh-ISI 8.7

6.Projection of market potentials

UU, PRI, all 5.2

7. Scenario calculations UU 3.7

8. Concluding evaluationFh-ISI/UU, CERISS, PRI, UCM, A&FI, all companies

14.8

9. ConferenceUU (in co-operation with Dechema)

1

10. Co-ordination UU 2.5

86.75

Final report *) Project partner underlined takes the lead. Bilateral and other small meetings are not shown in this graph. Interim report

Month of project

Work package Responsibility*)Person- months

Kic

koff

mee

tin

g

Fir

st P

len

ary

Sec

on

d P

len

ary

Th

ird

Ple

nar

y

Fo

urt

h P

len

ary

Fif

th P

len

ary

Co

nfe

ren

ce